A. Massey

发表

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

T. Hickish, D. Cunningham, I. Chau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma

D. Cunningham, G. Aherne, P. Ross, 2000, British Journal of Cancer.

Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.

A. Norman, D. Tait, Gina Brown, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

A. Norman, D. Cunningham, N. Maisey, 2005, British Journal of Cancer.

Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC)

D. Cunningham, I. Chau, N. Botwood, 2004 .

305 Twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief

A. Norman, D. Tait, Gina Brown, 2003 .

1097 – A prospective randomlsed trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer

A. Padhani, A. Norman, D. Cunningham, 1997 .

Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma

Gina Brown, A. Wotherspoon, D. Cunningham, 2005 .

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

D. Tait, A. Wotherspoon, D. Cunningham, 2010, The Lancet. Oncology.

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

D. Kerr, T. Powles, Y. Drew, 2020, The Lancet Oncology.

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer

A. Norman, D. Cunningham, I. Chau, 2001, British Journal of Cancer.

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.

A. Padhani, A. Norman, D. Cunningham, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.

L. Assersohn, T. Hickish, A. Norman, 2003, European journal of cancer.

A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

H. Mackay, R. Glasspool, D. Cunningham, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer

A. Norman, D. Tait, A. Wotherspoon, 2003, British Journal of Cancer.

Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC).

D. Cunningham, I. Chau, N. Botwood, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose finding study of irinotecan hydrochloride trihydrate (CPT11) with tomudex (TX.) in patients with 5-FU refractory colorectal cancer

D. Cunningham, P. Ross, G. Gruia, 1997 .